Junshi Biosciences, a China-based biotechnology company, agreed to invest $50m in Coherus BioSciences, a biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. “We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates. We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs," Ning LI, Junshi Biosciences CEO.